Trevena’s (TRVN) Neutral Rating Reaffirmed at HC Wainwright

Trevena (NASDAQ:TRVN)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Thursday, MarketBeat.com reports. They presently have a $5.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 197.62% from the stock’s previous close. HC Wainwright also issued estimates for Trevena’s Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.37) EPS and Q4 2025 earnings at $0.18 EPS.

Separately, StockNews.com began coverage on shares of Trevena in a research report on Monday, November 11th. They issued a “sell” rating for the company.

Trevena Trading Down 0.6 %

Shares of NASDAQ:TRVN opened at $1.68 on Thursday. The firm’s 50 day moving average is $3.05 and its two-hundred day moving average is $5.64. The firm has a market capitalization of $1.44 million, a P/E ratio of -0.04 and a beta of 1.08. Trevena has a 52 week low of $1.13 and a 52 week high of $19.23.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The business had revenue of $0.28 million during the quarter. Analysts predict that Trevena will post -32.25 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.